Thermo Fisher (TMO) Stock May Be Undervalued as Guidance Rises

According to a Simply Wall St analysis, Thermo Fisher Scientific (TMO) stock may be undervalued after the company raised its forward guidance. The Discounted Cash Flow (DCF) model indicates an intrinsic value 32% above the current share price of US$532.48.

Guidance Change

Thermo Fisher raised its financial guidance for fiscal 2026, citing strong demand for its life sciences and diagnostics solutions. Specific figures were not disclosed in this analysis.

Analyst Rationale

The DCF model discounts expected future cash flows to estimate intrinsic value. The results suggest the stock trades below its fair value, offering a potential opportunity for long-term investors. The 32% annual return over the past 12 months reflects market optimism but remains below the estimated intrinsic value.

Context

Despite the stock's strong performance, broader valuation metrics present a mixed picture. Recent acquisitions and collaborations in mRNA therapies bolster growth prospects but carry execution risks.

Conclusion

Thermo Fisher appears to have solid fundamentals with raised guidance, potentially making its stock attractive for value investors. However, sector and competition risks should be considered before any investment decision.